Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects
Event:
ESC Congress 2020
Topic:
Clinical
Session:
Advances in Chronic Thromboembolic Pulmonary Hypertension
